1. lets just start with Cowen, at whose event the CEO speaks on 3/4. The Cowen analyst priced srpt at $55 target, assuming no AA and more importantly, ZERO UK revenues, EVER. Needless to say, the Cowen analyst, and all the others, will be materially revising their annual numbers, starting no later than 2016.
2. the sprt partnership opportunity, in terms of value and timing, is now totally changed to the upside. No explanation needed for anybody with an IQ over .2
3. Do NOT underestimate this one: all of the entities who were wed to GSK behind the scenes, because GSK funds them (names not mentioned to protect the scummy/guilty, but you can throw ppmd and mda in that list), will now have to re-evaluate their "options". Ditto this times infinity for all the hedge funds who are short srpt on the promise of GSK doing the dirty on srpt.
4. The FDA. NOW WE KNOW HOW AND WHY ON GOD'S GREEN EARTH, THAT WOODCOCK AND TEMPLE WERE DOING THE PUBLIC THINGS THEY DID. THEY "KNEW" ALL ABOUT GSK'S SECRET.
And here is another statement that might seem crazy. Alexion has sales of 1.2B. Let's say with GSK folding in the Arena that Eteplirsen can now have sales of 1B and the MicroKid estimates that the whole MD platform is worth 3-4 times that. Alexion's Mkt Cap is 17B ours is 800M...and that isn't counting Hemorgic fevers, Flu, and TB. I would not be shocked to see a Pharmasett sized takeout happen soon.